
News|Videos|January 17, 2017
An Overview of the NeoMONARCH Trial in HR+/HER2- Breast Cancer
Author(s)Sara A. Hurvitz, MD
Sarah Hurvitz, MD, gives an overview of the neoMONARCH trial in hormone receptor-positive, HER2-negative breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























